Sun Pharmaceutical Industries has announced plans to acquire US-based healthcare company Organon in a $11.75 billion deal, making it one of the biggest overseas acquisitions by an Indian company and the largest by an Indian pharma firm.
The acquisition is expected to significantly strengthen Sun Pharma’s global presence and diversify its product portfolio. Organon has a strong business in women’s health, biosimilars and established medicines, with operations across more than 140 countries.
Sun Pharma said the deal supports its long-term growth strategy and will help it expand in high-potential global healthcare segments. Industry experts believe Organon’s established brands and international reach can provide steady revenue growth for the Indian drugmaker.
The combined business is expected to have wider global reach, stronger product offerings and improved scale in key markets such as the US, Europe and emerging economies.
The transaction has been approved by the boards of both companies and is expected to close after regulatory and shareholder clearances.
Investors reacted positively to the announcement, with Sun Pharma shares gaining in early trade. Analysts said the acquisition reflects the growing confidence of Indian pharmaceutical companies in making large global bets.
Also Read: Trump hosts Crypto event as meme coin crashes